Edesa Biotech, Inc. (EDSA)

NASDAQ: EDSA · IEX Real-Time Price · USD
1.01
+0.02 (2.54%)
Dec 5, 2022 3:40 PM EST - Market open
2.54%
Market Cap 18.97M
Revenue (ttm) n/a
Net Income (ttm) -18.42M
Shares Out 15.46M
EPS (ttm) -1.13
PE Ratio n/a
Forward PE 0.17
Dividend n/a
Ex-Dividend Date n/a
Volume 63,228
Open 1.01
Previous Close 0.98
Day's Range 0.97 - 1.02
52-Week Range 0.76 - 6.5
Beta 1.81
Analysts Buy
Price Target 16.66 (+1,557.7%)
Earnings Date Dec 28, 2022

About EDSA

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal ... [Read more]

Industry Biotechnology
Founded 2015
Employees 16
Stock Exchange NASDAQ
Ticker Symbol EDSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for EDSA stock is "Buy." The 12-month stock price forecast is 16.66, which is an increase of 1,557.71% from the latest price.

Price Target
$16.66
(1,557.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

TORONTO, ON / ACCESSWIRE / December 2, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. ...

3 days ago - Accesswire

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

TORONTO, ON / ACCESSWIRE / November 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases...

1 month ago - Accesswire

What Is Going on With Edesa Biotech (EDSA) Stock Today?

Amid a soft opening performance for the major equity indices, Edesa Biotech (NASDAQ: EDSA ) shot up 7% against the prior session before dipping into negative territory during the afternoon session. The ...

2 months ago - InvestorPlace

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Mortality reduction in critically ill subjects at 28 days revised favorably, statistically significant EB05 demonstrated an 84% reduction in the risk of dying when compared to placebo Clinical Study Rep...

2 months ago - Accesswire

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par...

2 months ago - Accesswire

Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment

Primary Endpoint To Be Reached Within 30 Days, With Topline Data Available by End of Year Company Evaluating Partnership and Out-Licensing Opportunities Outside North America for Its First-in-Class, Ant...

2 months ago - Accesswire

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech,...

3 months ago - Accesswire

Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference

TORONTO, ON / ACCESSWIRE / August 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that its ex...

4 months ago - Accesswire

Edesa Biotech to Present at ARDS Drug Development Summit

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nij...

4 months ago - Accesswire

Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the comp...

6 months ago - Accesswire

Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijh...

6 months ago - Accesswire

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial resu...

6 months ago - Accesswire

Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected

Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-in-class, anti-inflammatory drug TORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa ...

7 months ago - Accesswire

Edesa Biotech Appoints Strategy Expert to Board of Directors

TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appoint...

8 months ago - Accesswire

Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering

TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing...

8 months ago - Accesswire

Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has...

8 months ago - Accesswire

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update...

9 months ago - Accesswire

Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

9 months ago - Accesswire

Edesa Biotech to Join Ontario Bioscience Panel Discussion

TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. ...

10 months ago - Accesswire

Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy

Health Canada has approved to test Edesa Biotech Inc's (NASDAQ: EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically ill patients in the Phase 3 part of a Phas...

10 months ago - Benzinga

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy

Phase 3 study will focus on critically ill patients, many of whom have run out of effective drug treatment options TORONTO, ON / ACCESSWIRE / January 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clin...

10 months ago - Accesswire

Edesa Biotech Reports Fiscal Year 2021 Results

TORONTO, ON / ACCESSWIRE / December 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial...

11 months ago - Accesswire

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it h...

1 year ago - Accesswire

Edesa Biotech Extends COVID-19 Clinical Study to Poland

Expansion to European Union country follows favorable Phase 2 results Company focusing on critically ill hospitalized patients TORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc. (NASDAQ:E...

1 year ago - Accesswire

Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions

Edesa Biotech Inc (NASDAQ: EDSA) has announced additional results from the Phase 2 part of an ongoing Phase 2/3 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related:   Ed...

1 year ago - Benzinga